Loading...
XNASDVAX
Market cap1.66bUSD
Jan 10, Last price  
12.63USD
1D
0.08%
1Q
21.09%
Jan 2017
219.75%
Name

Dynavax Technologies Corp

Chart & Performance

D1W1MN
XNAS:DVAX chart
P/E
—
P/S
7.15
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.60%
Rev. gr., 5y
95.19%
Revenues
232m
-67.86%
14,812,00014,655,0004,847,00014,093,00037,094,00040,318,00023,950,00021,614,0009,714,00011,251,00011,032,0004,050,00011,043,000327,0008,198,00035,219,00046,551,000439,442,000722,683,000232,284,000
Net income
-6m
L
-15,971,000-20,555,000-52,052,000-59,971,000-20,829,000-30,565,000-57,308,000-48,597,000-69,949,000-66,720,000-90,722,000-106,794,000-112,444,000-95,154,000-158,899,000-151,397,000-91,776,00076,713,000293,156,000-6,389,000
CFO
101m
+60.35%
-7,332,000-22,858,000-37,240,000-32,032,000-17,035,000-33,552,000-51,370,000-47,116,000-43,809,000-58,673,000-73,738,000-92,559,000-107,051,000-77,518,000-131,301,000-121,252,000-92,251,000335,528,00062,716,000100,563,000
Earnings
Feb 20, 2025

Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
URL
https://www.dynavax.com/
IPO date
Feb 19, 2004
Employees
351
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
232,284
-67.86%
722,683
64.45%
Cost of revenue
257,999
440,161
Unusual Expense (Income)
NOPBT
(25,715)
282,522
NOPBT Margin
39.09%
Operating Taxes
2,022
1,143
Tax Rate
0.40%
NOPAT
(27,737)
281,379
Net income
(6,389)
-102.18%
293,156
282.15%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,360
9,639
BB yield
-0.35%
-0.60%
Debt
Debt current
4,496
3,631
Long-term debt
286,634
290,811
Deferred revenue
Other long-term liabilities
60,411
384
Net debt
(451,172)
(330,160)
Cash flow
Cash from operating activities
100,563
62,716
CAPEX
(4,104)
(7,139)
Cash from investing activities
(153,928)
(315,995)
Cash from financing activities
1,386
19,525
FCF
61,048
132,875
Balance
Cash
742,302
624,395
Long term investments
207
Excess cash
730,688
588,468
Stockholders' equity
(932,562)
(929,505)
Invested Capital
1,871,959
1,768,912
ROIC
16.20%
ROCE
33.66%
EV
Common stock shares outstanding
128,733
150,797
Price
13.98
31.39%
10.64
-24.38%
Market cap
1,799,687
12.17%
1,604,480
-14.26%
EV
1,348,515
1,274,320
EBITDA
(18,439)
289,190
EV/EBITDA
4.41
Interest
6,757
6,732
Interest/NOPBT
2.38%